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Acute coagulopathy of trauma: hypoperfusion induces systemic
anticoagulation and hyperfibrinolysis
Abstract
BACKGROUND: Coagulopathy is present at admission in 25% of trauma patients, is associated with
shock and a 5-fold increase in mortality. The coagulopathy has recently been associated with systemic
activation of the protein C pathway. This study was designed to characterize the thrombotic, coagulant
and fibrinolytic derangements of trauma-induced shock. METHODS: This was a prospective cohort
study of major trauma patients admitted to a single trauma center. Blood was drawn within 10 minutes
of arrival for analysis of partial thromboplastin and prothrombin times, prothrombin fragments 1 + 2
(PF1 + 2), fibrinogen, factor VII, thrombomodulin, protein C, plasminogen activator inhibitor-1 (PAI-1),
thrombin activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (tPA), and D-dimers.
Base deficit was used as a measure of tissue hypoperfusion. RESULTS: Two hundred eight patients
were studied. Systemic hypoperfusion was associated with anticoagulation and hyperfibrinolysis.
Coagulation was activated and thrombin generation was related to injury severity, but acidosis did not
affect Factor VII or PF1 + 2 levels. Hypoperfusion-induced increase in soluble thrombomodulin levels
was associated with reduced fibrinogen utilization, reduction in protein C and an increase in TAFI.
Hypoperfusion also resulted in hyperfibrinolysis, with raised tPA and D-Dimers, associated with the
observed reduction in PAI-1 and not alterations in TAFI. CONCLUSIONS: Acute coagulopathy of
trauma is associated with systemic hypoperfusion and is characterized by anticoagulation and
hyperfibrinolysis. There was no evidence of coagulation factor loss or dysfunction at this time point.
Soluble thrombomodulin levels correlate with thrombomodulin activity. Thrombin binding to
thrombomodulin contributes to hyperfibrinolysis via activated protein C consumption of PAI-1.
Title: 
Acute coagulopathy of trauma: hypoperfusion induces systemic 
anticoagulation and hyperfibrinolysis 
Short Title: Acute Traumatic Coagulopathy 
 
Authors: 
Karim Brohi, FRCS, FRCA, Mitchell J. Cohen, MD, Michael T. Ganter, MD, 
Marcus J. Schultz, MD, PhD, FCCS, Marcel Levi, MD, PhD, Robert C. 
Mackersie, MD, and Jean-Franc¸ois Pittet, MD 
 
Author affiliations: 
From the Department of Surgery, The Royal London Hospital (K.B.), London, United 
Kingdom; Departments of Surgery (M.J.C., R.C.M., J.F.P.) and Anesthesia (M.T.G., 
J.F.P.), San Francisco General Hospital, University of California San Francisco, San 
Francisco, California; and the Departments of Intensive Care, Laboratory of 
Experimental Intensive Care and Anesthesiology (M.J.S.) and Internal Medicine (M.L.), 
Academic Medical Center, Amsterdam, The Netherlands. 
 
Corresponding Author: 
Karim Brohi 
Department of Surgery, The Royal London Hospital 
Whitechapel Road, London, E1 1BB, United Kingdom 
Phone:  020 7377 7695     Fax: 020 7377 7044 
E-mail: karim@trauma.org 
 Sources of Support: 
This work was supported in part by grant R01 GM62188 from the National Institute of 
Health.  Assays of prothrombin fragments 1+2, thrombomodulin, protein C, tissue 
plasminogen activator and plasminogen activator inhibitor-1 were performed by Ely Lilly 
and Company. The supporting bodies had no role in the conduct of the study or the 
drafting of the manuscript. 
 
Meetings Presented: 
Part of this work was presented at ‘Trauma, Shock, Inflammation & Sepsis 2007’, 
Munich, Germany, March 2007.  
 
Abstract 
Background: Acute traumatic coagulopathy, present on admission in 25% of 
trauma patients, is associated with shock and a 5-fold increase in mortality.  The 
coagulopathy has recently been associated with systemic activation of the 
protein C pathway.  This study was designed to fully characterize the 
coagulopathy of shock and the resultant thrombotic, coagulant and fibrinolytic 
derangements.   
Methods: This was a prospective cohort study of major trauma patients admitted 
to a single trauma center.  Blood was drawn within 10 minutes of arrival for 
analysis of partial thromboplastin and prothrombin times, prothrombin fragments 
1+2 (PF1+2), fibrinogen, factor VII, thrombomodulin, protein C, plasminogen 
activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), 
tissue plasminogen activator (tPA) and D-dimers. Base deficit was used as a 
measure of tissue hypoperfusion.   
Results: 208 patients were studied.  Systemic hypoperfusion was associated 
with anticoagulation and hyperfibrinolysis.  Thrombin generation was related to 
injury severity, but acidosis did not affect Factor VII or PF1+2 levels.  
Hypoperfusion-induced increase in soluble thrombomodulin levels was 
associated with reduced fibrinogen utilization, reduction in protein C and an 
increase in TAFI.  Hypoperfusion also resulted in hyperfibrinolysis, with raised 
tPA and D-Dimers.  This was associated with the observed reduction in PAI-1 
and not alterations in TAFI. 
Conclusions: Acute traumatic coagulopathy is due to systemic hypoperfusion 
and is characterized by systemic anticoagulation and hyperfibrinolysis.  There 
was no evidence of coagulation factor loss or dysfunction at this time point. 
Soluble thrombomodulin levels appear to correlate with thrombomodulin activity.  
Thrombin-thrombomodulin leads to hyperfibrinolysis via activated protein C 
consumption of PAI-1.  
Introduction 
Acute traumatic coagulopathy is present immediately on admission in 25% of 
trauma patients and is associated with a 5-fold increase in mortality1.  Accepted 
causes of traumatic coagulopathy are consumption of clotting factors, acidosis 
and hypothermia leading to reduced activity, and dilution from intravenous fluids 
and packed cell administration.  However acute coagulopathy is present early in 
the post-injury phase, prior to fluid administration and in normothermic patients1.  
Further, while acidosis per se affects coagulation protease function, clot time and 
maximum clot firmness are only impaired at very low pH (<6.8)2. 
 
We have recently demonstrated that only patients who are in shock are 
coagulopathic on admission3.  Increased severity of hypoperfusion was 
associated with an increase in plasma thrombomodulin and a reduction in protein 
C levels.  This suggests that acute coagulopathy is due to systemic 
anticoagulation due to activation of the protein C pathway.   
 
The overall goal of this study was to fully characterize the coagulopathy of shock, 
and in particular to examine the interplay of shock, anticoagulation and the 
fibrinolytic system.  Secondly, we wished to determine whether coagulation factor 
consumption or dysfunction due to acidosis were responsible for coagulopathy 
prior to massive fluid and blood transfusion.  Third, we hypothesized that 
thrombomodulin has a central role in traumatic coagulopathy, complexing 
thrombin and resulting in anticoagulation and hyperfibrinolysis.  Finally, there has 
been some debate from basic science studies as to whether the hyperfibrinolysis 
resulting from thrombin-thrombomodulin formation is due to activation of 
Thrombin Activatable Fibrinolysis Inhibitor (TAFI)4 or activated protein C 
consumption of PAI-15,6.  We sought to understand which pathway was more 
important in clinical practice.  
 
Methods 
This was a prospective cohort study of consecutive major trauma patients 
admitted to a single level 1 trauma center.  The methodology has been described 
previously3.  Briefly, a 10 ml sample of blood was drawn by a designated member 
of the trauma team immediately on admission to the emergency department. The 
sample was spun down, plasma extracted and frozen at -80oC.   For this study 
we assayed plasma levels of Factor VII (+++++), tissue Plasminogen Activator 
(tPA) - Asserachrom tPA, Diagnostica Stago (normal range 3-13 ng/ml) and TAFI 
ELISA, Enzyme Research Laboratories (normal range: 2.8 - 9.2 mcg/ml) in 
addition to previously described measurements of Prothrombin Fragments 1+2 
(PF1+2), Fibrinogen, soluble Thrombomodulin (sTM), protein C, Plasminogen 
Activator Inhibitor-1 (PAI-1) and D-Dimer levels.  For the D-Dimer assay, levels 
above 0.22 μg/ml were reported as 0.22 μg/ml. 
 
Data were collected prospectively on patient demographics, injury time, 
mechanism (blunt or penetrating) and severity, prehospital fluid administration, 
the time of arrival in the trauma room and admission vital signs.  In the absence 
of a biochemical marker, the injury severity score was used as a surrogate 
measure of the degree of tissue injury.  A full blood count, coagulation profile and 
arterial blood gas were drawn at the same time as the research sample as part of 
the standard management of major trauma patients.  The degree of shock and 
systemic tissue hypoperfusion was assessed with the base deficit.  Admission 
base deficit is a clinically useful early marker of tissue hypoperfusion in trauma 
patients and an admission base deficit greater than 6 mEq/l has previously been 
identified as predictive of worse outcome in trauma patients.7,8 
 
Statistical analyses were performed with Microsoft Excel 2003 with the WinSTAT 
plug-in.  Normal-quantile plots were used to test for normal distribution.  
Parametric data are expressed as mean ± 95% confidence intervals.  Non-
parametric data are given as median (inter-quartile range).  Two-group analysis 
was performed with a two-tailed unequal variance Student’s t-test.  The χ2 test 
was used for dichotomous data analysis. A p-value of 0.05 was chosen to 
represent statistical significance. 
 
Results 
Blood was drawn on 208 consecutive patients immediately on arrival to the 
trauma room.  Median prehospital time was 28 minutes (interquartile range - IQR: 
23-29) and 150 mls of fluids (0-200) were administered in the field.  Median injury 
severity score was 17 (9-26) and 25% were penetrating.   
 
Patients without shock (base deficit - BD≤6) were not coagulopathic, regardless 
of injury severity (Fig 1, A&B).  2.6% of patients with a BD≤6 had a prolonged PT 
(>18s) compared to 19.6% of patients with BD>6 (p=0.001, χ2) and only 1.9% of 
patients with a BD≤6 had a prolonged PTT (>60s) compared to 12.5% of patients 
with BD>6 (p=0.007, χ2).  For patients in shock, both PT and PTT were 
prolonged as injury severity increased (Fig 1, A&B).  In contrast, there was 
activation of fibrinolysis without shock (Fig 1C).  However shock increased the 
degree of fibrinolysis in all patients (Fig 1D).  Acute coagulopathy is therefore a 
consequence of shock and is characterized by systemic anticoagulation and 
hyperfibrinolysis.  
 
Prothrombin fragments 1+2 (PF1+2) were assayed to assess the degree of 
thrombin generation.   PF1+2 increased with injury severity (Fig 2A).  There was 
no reduction in PF1+2 levels as acidosis increased (fig 2B), suggesting that 
reduction in coagulation factor activity due to acidosis does not make a 
significant contribution to the coagulopathy of shock.  Factor VII levels were also 
unchanged by acidosis (Fig 2C), and sufficient for clot generation.  Combined, 
these data also suggest that consumption of factors is not clinically significant at 
this time point and does not contribute to acute coagulopathy. 
 
We previously demonstrated that increasing shock with hypoperfusion was 
associated with a rise in plasma levels of soluble thrombomodulin (sTM) and a 
decrease in protein C levels3.  Thrombomodulin complexes with thrombin and 
switches it to an anticoagulant function.  Thrombin is therefore not free to cleave 
fibrinogen to form fibrin.  As thrombomodulin levels rise, fibrinogen levels also 
rise (figure 3A).  Figure 3B shows how with low thrombomodulin levels, there is a 
dose-dependent reduction in fibrinogen levels.  This effect is abolished when 
thrombomodulin is high.  Thus in the presence of shock and high 
thrombomodulin levels, fibrin production is minimal, regardless of clotting factor 
activity.   
 
Further consequences of formation of the thrombin-thrombomodulin complex 
include activation of protein C.  We did not measure activated protein C in this 
study but can demonstrate falling protein C levels with increasing sTM (Fig 3C) 
and have previously shown that this is likely to represent protein C activation due 
to observed effects on anticoagulation3.  Thrombin complexed to thrombomodulin 
also activates TAFI, and we can demonstrate an increase in TAFI levels with 
increasing sTM (Fig 3D).   Together these results support a central role for 
thrombomodulin in acute traumatic coagulopathy. 
 
We have demonstrated that systemic fibrinolysis is also a component of this 
coagulopathy (Fig 1C).  Tissue Plasminogen Activator (tPA) is released from the 
endothelium, and was significantly elevated in patients with shock, irrespective of 
the amount of thrombin generated (Fig 4, A&B). tPA levels were significantly 
higher when PAI-1 was low (Fig 4C) and increasing tPA levels were correlated 
with increasing D-Dimers, as expected (Fig 4D). 
 When present in excess, activated protein C is a potent inhibitor of PAI-14 and 
we have previously shown that patients in shock have low levels of PAI-1 and a 
direct correlation between protein C and PAI-1 levels, suggesting that protein C 
activation leads to PAI-1 consumption3.   It has previously been suggested that 
the de-inhibition of fibrinolysis seen with protein C is not due to this mechanism 
but to a competitive reduction in TAFI activation by the thrombin-thrombomodulin 
complex5,6.  We can demonstrate this competitive binding of T-TM to either 
protein C or TAFI by an inverse correlation between protein C and TAFI levels 
(Fig 5A).  However while we can demonstrate an inverse relationship between 
PAI-1 and the D-Dimer level (Fig 5B) there is no such correlation between TAFI 
and D-Dimers (Fig 5C) suggesting that in the clinical setting the protein C - PAI-1 
interaction is more important for the observed hyperfibrinolytic state. 
 
Discussion 
Acute traumatic coagulopathy occurs in patients who are shocked and is not due 
to coagulation factor consumption or dysfunction due to acidosis or dilution.  
These factors may be important later in the clinical course, after massive 
transfusion or the development of severe acidosis.  However shock itself is 
associated with a coagulopathy that is due to the systemic activation of 
anticoagulant and fibrinolytic pathways.   
 
We have demonstrated previously that the protein C pathway is implicated in this 
process3, and show here the central role of thrombomodulin in the conversion of 
thrombin from its coagulant role to a regulator of clot formation.  Thrombomodulin 
is an endothelial protein that is present in normal endothelial cells.  Theoretically, 
activation leads to increased thrombomodulin expression on the surface of the 
endothelium, where it complexes thrombin which cleaves protein C at the 
endothelial protein C receptor.  This ‘anticoagulant thrombin’ is no longer 
available to cleave fibrinogen to form fibrin, as we have demonstrated.  This has 
significant implications for current practice.  All efforts to correct traumatic 
coagulopathy are currently directed at augmenting the clotting factor pathway, 
through the administration clotting factors and platelets, e.g. fresh frozen plasma9 
or recombinant Factor VIIa10.  In theory, while patients are shocked and 
thrombomodulin is present in excess, thrombin that is generated will be 
anticoagulant, and stable clot will not be formed.  Although it may be possible to 
overwhelm thrombomodulin with massive thrombin generation, this would also be 
associated with widespread activation of protein C.  This would lead to 
consumption of PAI-1 and increased fibrinolysis, breaking down the clot that had 
formed.  Further, activated protein C has a relatively long half-life11, and the 
anticoagulant environment might persist and result in re-bleeding.  Further 
studies will be needed to ascertain whether this is mechanism is important 
following augmentation of the extrinsic pathway during shock. 
 
There has been some debate in the literature about the relationship between 
soluble thrombomodulin (sTM) and endothelial-bound thrombomodulin (eTM).  
Studies variously suggest that sTM does not reflect endothelial TM activity but is 
simply a marker of endothelial injury12, is itself active13,14 or that it is in fact 
inhibitory to the accepted role of thrombomodulin15,16. Our data would suggest 
that plasma sTM levels do reflect overall thrombomodulin activity, as increased 
sTM levels appear to be associated with decreased fibrinogen utilization and 
activation of protein C & TAFI. 
 
Finally, we have demonstrated that the increased fibrinolysis associated with 
injury is also due to shock and is mediated through de-inhibition of tPA through 
the consumption of PAI-1.  As mentioned above, it has been suggested that TAFI 
is the main driver of fibrinolysis inhibition, and that reduction in TAFI activation by 
the competitive binding of protein C to thrombin-thrombomodulin is the 
mechanism for de-repression of fibrinolysis with activation of protein C.  Although 
we can demonstrate an increase in TAFI levels with thrombomodulin, and a 
competition between TAFI and protein C, there was no observable correlation 
between TAFI and D-Dimer levels.  Thus the consumption of PAI-1 by activated 
protein C appears to be the more important cause of hyperfibrinolysis. 
 
This study has several limitations that have been alluded to previously3.  The PT 
and PTT are very crude methods of identifying coagulopathic patients, and do 
not describe the global fibrinolytic state at all.  Comparing these biochemical 
markers to more functional methods such as viscoelastic coagulation analyses 
(e.g., thrombelastography™) might reveal more clinically relevant changes in 
coagulation.  Further, this is an investigation of the state of the coagulation 
system at a single time point.   Alterations in response to continued hemorrhage 
or successful resuscitation are worthy of further study.  Previous investigations at 
later time points have identified that patients become hypercoagulable17,18 and 
are at risk of thromboembolic complications19.  It is possible that this is a result of 
depletion of protein C following systemic activation, indeed a previous study has 
identified admission coagulopathy as an independent risk factor for later venous 
thromboembolism20. 
 
In summary we have identified that acute traumatic coagulopathy occurs only in 
the presence of shock and is characterized by systemic anticoagulation and 
hyperfibrinolysis mediated through the activation of thrombomodulin.   This has 
significant implications for the management of traumatic hemorrhage, and 
suggests that hypoperfusion must be corrected before the coagulation system’s 
hemostatic balance can be restored. 
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Fig 1: Shock induces anticoagulation and hyperfibrinolysis 
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Fig 2: Early Thrombin Generation is related to injury severity & not affected 
by acidosis 
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Fig 3:  Increased soluble thrombomodulin is associated with reduced fibrinogen utilization, reduction in protein C 
(activation) and an increase in TAFI. 
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Fig 4:  Activation of fibrinolysis 
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Fig 5: Hyperfibrinolysis is due to consumption of PAI-1, not a reduction in 
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